Related Experiment Video

Updated: May 12, 2026

Techniques to Induce and Quantify Cellular Senescence
06:51

Techniques to Induce and Quantify Cellular Senescence

Published on: May 1, 2017

33.0K

Research progress of cell senescence in Alzheimer's disease: mechanisms and therapy

Jingwen Cai1, Lin Yang2, Yuewei Xu3

  • 1Department of Pharmacy, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.

European Journal of Pharmacology
|May 4, 2025
PubMed

Insights

Cell senescence (CS) is a key factor in Alzheimer's disease (AD) pathogenesis. Targeting CS offers a promising new therapeutic strategy for AD, though mechanisms require further elucidation.

Area of Science:

  • Neurodegenerative diseases
  • Cellular biology
  • Pharmacology

Background:

  • Alzheimer's disease (AD) is a prevalent neurodegenerative disorder with limited therapeutic options.
  • Current AD treatments, like cholinesterase inhibitors, offer unsatisfactory outcomes.
  • Cell senescence (CS), a stress response, is increasingly implicated in AD pathogenesis.

Purpose of the Study:

  • To review Alzheimer's disease (AD) pathogenesis and the role of cell senescence (CS).
  • To explore CS-based therapeutic strategies for AD, including chemical agents and traditional Chinese medicine.
  • To assess the clinical feasibility and challenges of CS-targeted therapies for AD.

Main Methods:

  • Literature review of AD pathogenesis and cell senescence mechanisms.
  • Analysis of existing and potential CS-targeting drugs for AD.
  • Evaluation of clinical applications and challenges for CS-based AD treatments.

Main Results:

  • Cell senescence is a significant contributor to Alzheimer's disease progression.
  • CS presents a viable target for novel AD therapeutic interventions.
  • Both chemical and traditional Chinese medicine approaches show potential for CS-based AD therapy.

Conclusions:

  • Understanding the mechanisms of CS in AD is crucial for developing effective treatments.
  • CS-targeted therapies hold promise for improving clinical outcomes in Alzheimer's disease.
  • Further research is needed to overcome clinical challenges and optimize CS-based strategies for AD.
Keywords:
Alzheimer's diseaseCell senescenceGlial cellsInflammationMicroglia

More Related Videos

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

23.6K
Measurement of Protein Turnover Rates in Senescent and Non-Dividing Cultured Cells with Metabolic Labeling and Mass Spectrometry08:52

Measurement of Protein Turnover Rates in Senescent and Non-Dividing Cultured Cells with Metabolic Labeling and Mass Spectrometry

Published on: April 6, 2022

3.4K

Related Concept Videos

Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...